Rite Aid

Rite Aid Corp. engages in the ownership and management of retail drug stores. It operates through following segments: Retail Pharmacy and Pharmacy Services. The Retail Pharmacy segment includes branded and generic prescription drugs, health and beauty aids, personal care products, and walk-in retail clinics. The Pharmacy Services segment offers transparent and traditional pharmacy benefit management for insurance companies, employers, health plans, and government employee groups. The company was founded by Alex Grass on September 12, 1962 and is headquartered in Philadelphia, PA.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rite Aid Corp. engages in the ownership and management of retail drug stores. It operates through the Retail Pharmacy and Pharmacy Services segments. The Retail Pharmacy segment includes branded and generic prescription drugs, health and beauty aids, personal care products, and walk-in retail clinics. The Pharmacy Services segment offers transparent and traditional pharmacy benefit management for insurance companies, employers, health plans, and government employee groups. The company was founded by Alex Grass on September 12, 1962 and is headquartered in Philadelphia, PA.

Rite Aid is a health products and services company with 2,400 locations across 17 states.

The company's omnichannel business includes digital, retail, and delivery touchpoints. Rite Aid is a top 20 seller of speciality medications, per its investor website.

In addition to its retail business, Rite Aid owns a pharmacy benefits subdivision (Elixir) and a personalized health services and coaching arm, Health Dialog, which has served 10MM members as of May 2022.

The company has reported $1.85 billion of liquidity with no debt maturities until 2025. According to its investor website, Rite Aid expects to be free cash flow (FCF) positive in FY23.

In Q2 2022, Rite Aid shared a three-part growth strategy aimed at deepening market share, expanding into new markets, and creating new offerings.

To grow the current business, Rite Aid is aiming to increase its e-commerce and digital sales, refresh its loyalty program, and grow its specialty pharmacy offering, which focuses on serving customers with complex health conditions.

New market expansion plans include increasing Rite Aid's footprint of "small format" pharmacies in underserved communities and implementing "store within a store" partnerships.

Rite Aid also aims to grow via new offerings, such as expanded health plan and health system clinical services, a pharmacy benefit manager (PBM) as a service offering, and new strategic partnerships.

Rite Aid Investor Relations

*This is not investment advice.

Shares of Rite Aid Corp. RAD, +13.78% rocketed as much as 38.5% intraday before paring gains to be up 18.7% in very active afternoon trading Wednesday, after the New York Post reported that the drugstore chain rejected earlier this month a buyout bid that valued the company at more than $800 million. Trading volume swelled to about 16 million share, compared with the full-day average of about 4.3 million shares.

Rite Aid's stock rockets after the New York Post reported it rejected a buyout bid at a hefty premium

Rite Aid earlier this month quietly rejected a takeover bid that valued the drugstore chain at more than $800 million -- despite it being nearly twice the drugstore chain's current stock price, The Post has learned.

Rite Aid rejected $800M takeover bid this month

Drugstore operator Rite Aid Corporation (NYSE: RAD) stock has been pummeled since hitting a post-pandemic high of $32.48 on Jan. 28, 2021.

Rite Aid Stock is Getting Cheap Enough to Buy Here

GlaxoSmithKline

Pfizer

Health care stocks are making the rounds as the pandemic continues to pose challenges globally and high growth names lose steam.

Best Stocks To Buy Right Now? 3 Health Care Stocks In Focus

Rite Aid Corporation (NYSE:RAD ) Q4 2022 Earnings Conference Call April 14, 2022 8:30 AM ET Company Participants Byron Purcell - Investor Relations Heyward Donigan - President & CEO Matt Schroeder - EVP & CFO Andre Persaud - EVP & CRO, Elixir Chris DuPaul - COO, Elixir Conference Call Participants Michael Minchak - JPMorgan Elizabeth Anderson - Evercore ISI George Hill - Deutsche Bank Jenna Giannelli - Goldman Sachs William Reuter - BofA Securities Karru Martinson - Jefferies Carla Casella - JPMorgan Operator Good morning. My name is Rob, and I will be your conference operator today.

Rite Aid Corporation (RAD) CEO Heyward Donigan on Q4 2022 Results - Earnings Call Transcript

Rite Aid reported a strong close to the 2022 fourth quarter and full year, while also eyeing an outlook in 2023 that leads to the shuttering of 145 stores that have so far proven to be unprofitable. Amid struggles to compete with Walgreens, CVS Health and Walmart pharmacies, Rite Aid is looking to lower costs, […]

Rite Aid Posts Strong Year Amid Shuttering Unprofitable Stores

The company provided a better-than-expected outlook for fiscal 2023.

Why Rite Aid Stock Is Rebounding Today

The shares of Rite Aid Corporation (NYSE:RAD) are surging this morning, last seen up 15.9% to trade at $8.68, after the pharmacy giant reported fiscal fourth-quarter results.

Rite Aid's Sunny Forecast Attracts Options Traders

Rite Aid (RAD) stock is rising higher on Thursday thanks to the company's earnings report for the fourth quarter of fiscal 2022. The post Why Is Rite Aid (RAD) Stock Up 10% Today?

Why Is Rite Aid (RAD) Stock Up 10% Today?

Rite Aid expects to close a total of 145 “unprofitable stores” in ongoing cost-cutting moves designed to help the pharmacy chain be more competitive.

Rite Aid Expects More Closures Of ‘Unprofitable' Stores

Rite Aid Corp (NYSE: RAD) has reported Q4 FY22 sales of 6.06 billion, +2.5% Y/Y, beating the consensus of $5.95 billion. The Company reported an EPS loss of $(1.63) compared to $(0.78) a year ago.

Why Rite Aid Shares Are Soaring Today

Rite Aid Corporation stock (NYSE: RAD) opened more than 15% in premarket trading on Thursday after the pharmacy company reported strong revenue for its fiscal Q4 and gave better than expected guidance for the full year. Key takeaways from Rite Aid Q4 earnings report Net loss printed at $389.1 million versus the year ago figure […] The post Rite Aid stock opens 15% up on Thursday: what happened?

Rite Aid stock opens 15% up on Thursday: what happened?

Rite Aid Corp. RAD, +2.60% shares rose 6.8% in Thursday premarket trading after it reported fourth-quarter revenue that beat consensus and gave guidance ahead of Street expectations. The pharmacy retailer posted a net loss of $389.1 million, or $7.18 per share, after a loss of $18.5 million, or 34 cents per share, last year.

Rite Aid stock jumps after revenue beat and guidance ahead of Street expectations

PHILADELPHIA--(BUSINESS WIRE)--Rite Aid Corporation (NYSE: RAD) today reported operating results for its fourth quarter and fiscal year ended February 26, 2022. “We exceeded our 2022 plan amid continuing challenges of the COVID-19 pandemic. As we look forward to the year ahead, we are ready and energized to compete in a new post-pandemic normal,” said Heyward Donigan, president and chief executive officer. “We demonstrated the important role that pharmacists play in the everyday health of our c

Rite Aid Corporation Reports Strong Fiscal 2022 Fourth Quarter and Full Year Results and Provides Fiscal 2023 Outlook

Taiwan Semiconductor Manufacturing

UnitedHealth Group

While there were a few interesting earnings reports out Tuesday morning, all eyes were focused on the U.S.

Earnings Previews: Rite Aid, Taiwan Semiconductor, UnitedHealth

Rite Aid (RAD) is likely to have gained from strength in PBM, RxEvolution strategy and delivery services in Q4. Rising wage costs and higher payroll expenses are likely to have been concerns.

Factors Likely to Decide Rite Aid's (RAD) Fate in Q4 Earnings

Rite Aid (RAD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Rite Aid (RAD) Stock Jumps 7.4%: Will It Continue to Soar?

Rite Aid Corp (NYSE: RAD) is down 25% in the stock market on Thursday after a Deutsche Bank analyst said the drugstore chain might fail to continue as an “operating company”. George Hill has $1.0 a share price target George Hill downgraded the stock this morning to “sell” with a price target of $1.0 a […] The post Rite Aid might fail to ‘continue as an operating company' appeared first on Invezz.

Rite Aid might fail to ‘continue as an operating company'

Beyond Meat

Beyond Meat Inc. BYND, -1.19% announced Thursday that Beyond Meatballs and the Beyond Burger product will be available at about 2,000 Rite Aid Corp. RAD, -21.39% locations around the country. The pharmacy retailer is the latest addition to a long list of restaurant chains and retailers that carry the plant-based meat company's products.

Beyond Meat to begin selling at 2,000 Rite Aid locations

Rite Aid shares plunged on Thursday after Deutsche Bank downgraded the pharmacy retail chain and cut the stock's price target ahead of the release of its quarterly results next week.

Rite Aid shares tank on Deutsche Bank downgrade

Deutsche Bank said Rite Aid's upcoming 2023 guidance for annual adjusted EBITDA may be unattainable.

Rite Aid plummets 25% after Deutsche Bank slashes price target to $1 as COVID-19 'hastens the decline' of the company's retail pharmacy business

An analyst gave a bleak outlook for the pharmacy stock.

Why Rite Aid Stock Is Crashing Today

A Wall Street downgrade has Rite Aid plunging into the red. Here's what investors need to know about the future of RAD stock.

Why One Analyst Thinks Rite Aid (RAD) Stock Is Headed to $1

Rite Aid Corporation (NYSE:RAD) stock is crumbling today, down 17.9% to trade at $6.93, after a downgrade from Deutsche Bank to "sell" from "hold," with a price-target cut to $1 from $16.

Rite Aid Stock Rattled After Analyst Cuts Price Target to $1

Ahead of the Company's fiscal Q4 results on April 14, Deutsche Bank downgraded Rite Aid Corporation (NYSE: RAD) to Sell from Hold with a price target of $1, down from $16. Analyst George Hill believes COVID has "hastened the decline" for the Company, and he sees the.

News for Rite Aid Stock (RAD)